A new milestone in AD biomarker development published Nature Medicine: Plasma p-tau217 is at least non-inferior to FDA-approved CSF markers. Great collab between BioFINDER & Washington University Department of Neurology, with a special shout-out to Gemma Salvadó who is truly making an impact.